Eunbi Oh, Byung Sung Kim*, Sunyoung Kim, Jihyun Kim and Changwon Won
Department of Family Medicine, Kyung Hee University Hospital, Seoul, South KoreFulltext PDF
Background: Proton Pump Inhibitor (PPI) is one of the most widely used drugs in the world. Some studies have suggested that using PPI increases the risk of stomach cancer, but the conclusion is still controversial. Therefore, this study conducted a meta-analysis investigating the relationship between PPI use and stomach cancer. Materials and Methods: Through PubMed, EMBASE, and Cochrane Library databases, papers on PPI and gastric cancer risk were searched using 'proton pump inhibitor OR PPI' AND 'stomach OR gastric' and 'canner OR tumor OR malignancy' as search terms. The period was limited to placebocontrol studies and cohort studies for papers published from 2006 to 2021, and two researchers conducted a qualitative evaluation. For statistical analysis, a meta-analysis was performed using STATA version 17. Results: The Odds Ratio (OR) for the incidence of gastric cancer and PPI was 2.46 (95% CI, 2.36~2.56), which was associated stomach cancer. Through subgroup analysis by quality, the odds ratio of the high-quality group was 1.37 (95% CI 1.22~2.53), and the odds ratio of the low-quality group was 3.32 (95% CI, 3.18~3.46), which still showed the relationship between the high-quality group. Conclusion: As a result of analyzing the relationship between PPI and gastric cancer, PPI significantly increased the incidence of gastric cancer.
Stomach cancer; Proton pump inhibitors; Meta-analysis; Odds ratio
Oh E, Kim BS, Kim S, Kim J, Won C. Association between Proton Pump Inhibitor and Risk of Stomach Cancer: A Meta-Analysis of Epidemiologic Studies. Int J Fam Med Prim Care. 2022;3(3):1066.